To explore the significance of aberrant expression of p-ERK1/2 in TNBC for cancer targeted gene therapy of BikDD, we investigated the correlation between p-ERK1/2 expression and expression of Bik, Bcl-2, Bcl-Xl and Mcl-1 in 114 breast cancer patient samples. This evidence concerns the gene MCL1 and breast cancer.